Seres Therapeutics Awaits Key Data Readout as Cash Runway Narrows
Event summary
- Seres Therapeutics expects clinical data from an investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis in the coming weeks.
- The company reported a net loss of $19.9 million for Q1 2026, down from a net income of $32.7 million in Q1 2025.
- Seres has $29.8 million in cash and cash equivalents as of March 31, 2026, with a runway extending through Q3 2026.
- SER-155 is Phase 2 ready for preventing bloodstream infections in allo-HSCT patients, pending funding.
- Seres is advancing SER-603 for inflammatory bowel disease, with IND-enabling work progressing.
The big picture
Seres Therapeutics is navigating a critical phase with impending clinical data that could shape its strategic direction. The company's focus on live biotherapeutics in inflammatory and immune diseases comes amid a tightening cash position, necessitating successful partnerships or financing to sustain its pipeline. The broader biotech landscape continues to emphasize innovative microbiome therapeutics, with Seres positioning itself as a key player in this evolving field.
What we're watching
- Clinical Data Impact
- How the upcoming SER-155 data readout will influence development pathways and potential expansion opportunities.
- Funding Strategy
- Whether Seres can secure partnerships or other financing to support pipeline advancement and extend its cash runway.
- Pipeline Progress
- The pace at which Seres advances SER-603 and other preclinical programs in inflammatory and immune diseases.
Related topics